Fluoxetine: no association with suicidality in obsessive-compulsive disorder
| Autor: | Charles M. Beasley, Janet H. Potvin, Laura A. Genduso, David E. Wheadon, Daniel N. Masica, Bruce E. Dornseif |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Obsessive-Compulsive Disorder medicine.medical_specialty Serotonin uptake Placebo behavioral disciplines and activities Double-Blind Method Risk Factors Fluoxetine mental disorders medicine Humans Single-Blind Method Risk factor Psychiatry Suicidal ideation Depression (differential diagnoses) Dose-Response Relationship Drug Middle Aged medicine.disease Comorbidity Suicide Psychiatry and Mental health Clinical Psychology Female medicine.symptom Psychology Anxiety disorder medicine.drug |
| Zdroj: | Journal of Affective Disorders. 24:1-10 |
| ISSN: | 0165-0327 |
| Popis: | Since (a) obsessive-compulsive disorder (OCD) may involve serotonergic neural transmission abnormalities also thought to be related to regulation of suicide and aggression, (b) comorbidity between OCD and depression is substantial, and (c) depression is a major risk factor for suicide, a comprehensive analysis of clinical trial data was undertaken to assess the potential association of fluoxetine, a serotonin uptake inhibitor, and suicidality (suicidal acts and ideation). Pooled data from clinical trials comparing fluoxetine ( n =266) and placebo ( n =89) in patients with DSM-IIIR OCD were analyzed retrospectively. No suicidal acts occurred during placebo lead-in or double-blind therapy. Mean Hamilton Depression Scale item 3 (suicide item) scores improved statistically significantly with fluoxetine compared with placebo. Worsening in suicidal ideation was statistically significantly more frequent with placebo than with fluoxetine. Emergence of substantial suicidal ideation (change in baseline item 3 score of 0 or 1 to 3 or 4) was numerically greater with placebo than with fluoxetine (3.6% vs. 1.7%; not statistically significant). The incidence of suicidality in fluoxetine-treated patients with OCD was low, compared favorably with rates in corresponding placebo-treated patients, and was well within the range of estimates in previous studies of patients with OCD. These controlled clinical trial results suggest no undue risk of suicidality in patients with OCD treated with fluoxetine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|